Literature DB >> 33580008

Feasibility, potency, and safety of growing human mesenchymal stem cells in space for clinical application.

Peng Huang1,2, Athena L Russell1,2, Rebecca Lefavor1,2, Nisha C Durand1,2, Elle James1,2, Larry Harvey3, Cuiping Zhang1,2, Stefanie Countryman4, Louis Stodieck4, Abba C Zubair5,6.   

Abstract

Growing stem cells on Earth is very challenging and limited to a few population doublings. The standard two-dimensional (2D) culture environment is an unnatural condition for cell growth. Therefore, culturing stem cells aboard the International Space Station (ISS) under a microgravity environment may provide a more natural three-dimensional environment for stem cell expansion and organ development. In this study, human-derived mesenchymal stem cells (MSCs) grown in space were evaluated to determine their potential use for future clinical applications on Earth and during long-term spaceflight. MSCs were flown in Plate Habitats for transportation to the ISS. The MSCs were imaged every 24-48 h and harvested at 7 and 14 days. Conditioned media samples were frozen at -80 °C and cells were either cryopreserved in 5% dimethyl sulfoxide, RNAprotect, or paraformaldehyde. After return to Earth, MSCs were characterized to establish their identity and cell cycle status. In addition, cell proliferation, differentiation, cytokines, and growth factors' secretion were assessed. To evaluate the risk of malignant transformation, the space-grown MSCs were subjected to chromosomal, DNA damage, and tumorigenicity assays. We found that microgravity had significant impact on the MSC capacity to secrete cytokines and growth factors. They appeared to be more potent in terms of immunosuppressive capacity compared to their identical ground control. Chromosomal, DNA damage, and tumorigenicity assays showed no evidence of malignant transformation. Therefore, it is feasible and potentially safe to grow MSCs aboard the ISS for potential future clinical applications.

Year:  2020        PMID: 33580008     DOI: 10.1038/s41526-020-0106-z

Source DB:  PubMed          Journal:  NPJ Microgravity        ISSN: 2373-8065            Impact factor:   4.415


  42 in total

Review 1.  Molecular characteristics of bone marrow mesenchymal stem cells, source of regenerative medicine.

Authors:  Fatemeh Pourrajab; Seyed Khalil Forouzannia; Seyed Ahmad Tabatabaee
Journal:  Int J Cardiol       Date:  2011-12-02       Impact factor: 4.164

Review 2.  Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace.

Authors:  Chaomei Chen; Zhigang Hu; Shengbo Liu; Hung Tseng
Journal:  Expert Opin Biol Ther       Date:  2012-03-25       Impact factor: 4.388

3.  Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

Authors:  Igor B Resnick; Claudine Barkats; Michael Y Shapira; Polina Stepensky; Allan I Bloom; Avichai Shimoni; David Mankuta; Nira Varda-Bloom; Lyudmila Rheingold; Moshe Yeshurun; Bella Bielorai; Amos Toren; Tsila Zuckerman; Arnon Nagler; Reuven Or
Journal:  Am J Blood Res       Date:  2013-08-19

Review 4.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

5.  Modifiers of mesenchymal stem cell quantity and quality.

Authors:  Athena L Russell; Rebecca Lefavor; Nisha Durand; Loren Glover; Abba C Zubair
Journal:  Transfusion       Date:  2018-03-26       Impact factor: 3.157

6.  Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature.

Authors:  S Viswanathan; Y Shi; J Galipeau; M Krampera; K Leblanc; I Martin; J Nolta; D G Phinney; L Sensebe
Journal:  Cytotherapy       Date:  2019-09-13       Impact factor: 5.414

7.  Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

Authors:  Corinna Koebnick; Annette M Langer-Gould; Michael K Gould; Chun R Chao; Rajan L Iyer; Ning Smith; Wansu Chen; Steven J Jacobsen
Journal:  Perm J       Date:  2012

8.  Feasibility, Safety, and Tolerance of Mesenchymal Stem Cell Therapy for Obstructive Chronic Lung Allograft Dysfunction.

Authors:  Cesar Ariel Keller; Thomas Arthur Gonwa; David Orel Hodge; Derek Joseph Hei; John Michael Centanni; Abba Chedi Zubair
Journal:  Stem Cells Transl Med       Date:  2018-01-11       Impact factor: 6.940

9.  Safety and Efficacy of Intraventricular Delivery of Bone Marrow-Derived Mesenchymal Stem Cells in Hemorrhagic Stroke Model.

Authors:  Peng Huang; William D Freeman; Brandy H Edenfield; Thomas G Brott; James F Meschia; Abba C Zubair
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

10.  Comparative Analyses of Immunosuppressive Characteristics of Bone-Marrow, Wharton's Jelly, and Adipose Tissue-Derived Human Mesenchymal Stem Cells.

Authors:  Erdal Karaöz; Pınar Çetinalp Demircan; Gülay Erman; Eda Güngörürler; Ayla Eker Sarıboyacı
Journal:  Turk J Haematol       Date:  2016-09-09       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.